Matthew J. Genzink

Toward the Development of a Commercial Process to Produce Muvalaplin. Part II: Preparation of the Drug Substance

Abstract Herein, we describe the development of steps 5–7 for a large-scale process to synthesize muvalaplin, a small-molecule lipoprotein(a) inhibitor for the potential reduction of major adverse cardiovascular events in participants with established cardiovascular disease or at...